Email this article 
In Russia, a new indication for pembrolizumab in combination with axitinib in the first-line treatment of patients with advanced renal cell carcinoma has been approved
- Issue: Vol 15, No 4 (2019)
- Pages: 140-142
- Section: RESOLUTION
- Published: 30.12.2019
- URL: https://oncourology.abvpress.ru/oncur/article/view/1016
- ID: 1016
Cite item
Full Text
Abstract
.
References
- Malignant tumors in Russia in 2018 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTS radiologii” Minzdrava Rossii, 2019. 250 p. (In Russ.).
- Rini B.I., Plimack E.R., Stus V. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380(12):1116–27. doi: 10.1056/NEJMoa1816714.
Supplementary files
